1. Home
  2. KE vs PRME Comparison

KE vs PRME Comparison

Compare KE & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kimball Electronics Inc.

KE

Kimball Electronics Inc.

HOLD

Current Price

$24.67

Market Cap

564.2M

Sector

Technology

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.12

Market Cap

553.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KE
PRME
Founded
1961
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
564.2M
553.2M
IPO Year
2014
2022

Fundamental Metrics

Financial Performance
Metric
KE
PRME
Price
$24.67
$3.12
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$28.00
$7.56
AVG Volume (30 Days)
166.1K
2.4M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
66.18
18.18
EPS
1.13
N/A
Revenue
$1,431,378,000.00
$4,632,000.00
Revenue This Year
N/A
$7.06
Revenue Next Year
$4.57
$47.01
P/E Ratio
$21.79
N/A
Revenue Growth
N/A
55.28
52 Week Low
$21.60
$2.67
52 Week High
$32.47
$6.94

Technical Indicators

Market Signals
Indicator
KE
PRME
Relative Strength Index (RSI) 53.49 42.70
Support Level $23.59 $2.73
Resistance Level $26.77 $3.72
Average True Range (ATR) 0.84 0.22
MACD 0.08 -0.06
Stochastic Oscillator 65.38 19.89

Price Performance

Historical Comparison
KE
PRME

About KE Kimball Electronics Inc.

Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: